American judges declare limits on abortion medication to be illegal

A federal court in Virginia has deemed the US drug regulator's restrictions on mifepristone, the abortion pill, as "unlawful", and has instructed the Trump administration to reexamine these restrictions, which were imposed by the Food and Drug Administration.

n

The case, initiated by the nonprofit Center for Reproductive Rights in May 2023, was filed on behalf of abortion providers in Virginia, Kansas, and Montana, and challenged the rules known as Risk Evaluation and Mitigation Strategy (REMS) that have long been criticized by abortion advocates as overly restrictive.

n

One of the rules in question requires prescribers to register with the manufacturer, thereby creating a national database that could potentially put doctors at risk, while another mandates that pharmacies obtain special certification and maintain detailed records.

n

A third rule necessitates patients to review counseling that critics argue is inaccurate, sparking widespread controversy among abortion advocates who deem these restrictions as unduly burdensome.

n

In his ruling, Judge Robert S. Ballou described the new restrictions as "arbitrary and capricious", citing the FDA's longstanding finding that mifepristone is a safe and effective medication, a stance the agency has maintained over the past quarter century.

n

Although Judge Ballou ordered the Trump administration to reconsider the rules, he stopped short of voiding them and did not find that the FDA had acted illegally in principle by attempting to impose safety restrictions.

n

Nancy Northup, CEO of the Center for Reproductive Rights, hailed the ruling as "a win for science", emphasizing the significance of the court's decision in the ongoing debate surrounding mifepristone.

n

The case is distinct from another ongoing lawsuit in the Fifth Circuit, where the Republican-led state of Louisiana is seeking to reimpose a ban on patients receiving mifepristone by mail or through pharmacies after a virtual consultation with a provider.

n

In May, the US Supreme Court temporarily upheld mail access to mifepristone, extending its stay of the Fifth Circuit's order that had sided with Louisiana and would have halted such delivery, and the case is now pending at the federal appeals court for full briefings.

n

The case may eventually be appealed to the Supreme Court, as the legal battle surrounding mifepristone continues to unfold, with the drug having been approved by the FDA since 2000 and commonly used to manage miscarriages.

n

Since 2023, mifepristone has accounted for 63 percent of all US abortions, and while anti-abortion activists have raised concerns about the drug's safety, citing a study conducted by a conservative think tank, the FDA has ordered its own review of abortion pill regulations.